Tomahawk, WI 12/11/2013 (BasicsMedia) – Geron Corporation (NASDAQ:GERN) is a drugmaker company whose market value is $644.85 million. The company develops and sales drugs target at treat different human suffering. As a biopharm company, the stock of GERN rises and falls on FDA and related reports on the company’s products.

The latest positive news on one of its drugs has excited the market and investors and seen vying for position. However, the surge in interest in the stock seems to be baffling to some investors who are not sure to buy or stay away from the drugmaker. This is why analysts have weighed in to offer some guidance.

The stock has received upgrades in recent weeks which place its stock price at an average value of $6.63. GERN received price upgrade from Needham and Company to $10 per share. It also received positive recommendation of buy. Currently the stock is trading around $5 per share. It means that analysts are hoping that the stock will double in the upcoming weeks or even months.

Investors can therefore hold on their holdings while those wishing to share in the expected growth have the opportunity to get the stock when it is still cheap.

Corroborating the bullish future of Geron Corporation (NASDAQ:GERN) are analysts at MLV & Co. who have raise their target on the company to $9 per share, up from $8 per share. And they assign a buy rating on the stock. Given that analysts are seeing this stock surging going forward reveals the underlying benefits for investors who hope in early.

It is important noting that Geron Corporation (NASDAQ:GERN) is not just well positioned because of the latest news regarding its products, but the company is also observing cost reduction strategies which are expected to improve its bottom line. Moreover, the company’s pipeline is also well structured which means that it is still going to see incremental revenue as it gets.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.